It was registered an increase on Translate Bio Inc (NASDAQ:TBIO)’s shares shorted with 1.24%. In November was published TBIO’s total 40,800 shares shorted by FINRA. The up change of 1.24% from 40,300 shares was reported. Previous TBIO’s position will need 1 days to recover. It has 41,700 average volume. Translate Bio Inc float short is 0.15%.
TBIO is hitting $6.5 during the last trading session, after decreased 4.27%.Translate Bio, Inc. has volume of 56,153 shares. Since November 10, 2017 TBIO has 0.00% and is . TBIO underperformed by 15.62% the S&P 500.
Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction.The firm is valued at $293.42 million. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.Last it reported negative earnings. It has strategic alliances with Sanofi Pasteur.
Translate Bio, Inc. (NASDAQ:TBIO) Ratings Coverage
A total of 2 analysts rate Translate Bio (NASDAQ:TBIO) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:TBIO) has 2 ratings reports on Nov 10, 2018 according to StockzIntelligence.
For more Translate Bio, Inc. (NASDAQ:TBIO) news published recently go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Benzinga.com or Globenewswire.com. The titles are as follows: “Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Profit Tops Expectations” published on October 16, 2018, “Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights” on November 08, 2018, “Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis …” with a publish date: October 18, 2018, “The Daily Biotech Pulse: Illumina’s Strong Q3, Celgene’s Positive Cancer Drug Trial, Proteostasis Offering” and the last “Translate Bio to Participate in Upcoming Investor Conferences” with publication date: November 01, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.